{"id":134613,"date":"2026-03-18T07:02:49","date_gmt":"2026-03-18T07:02:49","guid":{"rendered":"https:\/\/chezaspin.com\/blog\/indias-cheap-weight-loss-drugs-could-reshape-global-obesity-fight\/"},"modified":"2026-03-18T07:02:49","modified_gmt":"2026-03-18T07:02:49","slug":"indias-cheap-weight-loss-drugs-could-reshape-global-obesity-fight","status":"publish","type":"post","link":"https:\/\/chezaspin.com\/blog\/indias-cheap-weight-loss-drugs-could-reshape-global-obesity-fight\/","title":{"rendered":"India\u2019s cheap weight-loss drugs could reshape global obesity fight"},"content":{"rendered":"

India could soon get a lot thinner \u2013 at least in theory.<\/strong><\/p>\n

On Friday the patent on semaglutide \u2013 the molecule behind Danish drugmaker Novo Nordisk\u2019s blockbuster weight-loss drugs Wegovy and Ozempic \u2013 expires in the country.<\/p>\n

This will allow domestic pharmaceutical companies to release cheaper copies or generics, triggering a rush of competition that could slash prices by more than half and rapidly expand access for people in India, and eventually in other countries too.<\/p>\n

Investment bank Jefferies has called it a potential \u201cmagic-pill moment\u201d for India, predicting the semaglutide market could eventually reach $1bn domestically with the right pricing and uptake.<\/p>\n

Analysts expect around 50 branded semaglutide generics to enter the market within months \u2013 a familiar pattern in India\u2019s fiercely competitive pharmaceutical industry. When the diabetes drug sitagliptin went off patent in 2022, about 30 branded versions appeared within a month and nearly 100 within a year.<\/p>\n

India\u2019s pharmaceutical industry, currently worth about $60bn, is expected to double by 2030. Much of it is built on generics \u2013 a manufacturing muscle that now sets the stage for fierce competition over semaglutide. What has until now been an expensive injection largely confined to affluent patients could soon become far more common.<\/p>\n

Originally developed to treat diabetes, these drugs are now being hailed as game changers for weight loss, offering results that few previous treatments could match. Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar.<\/p>\n

By boosting insulin release and slowing the emptying of the stomach, the drugs make people feel full sooner and stay full longer. Originally developed for diabetes, they have become some of the most sought-after weight-loss treatments in the world.<\/p>\n

Several Indian drugmakers are already preparing to make the move. According to Sheetal Sapale, vice-president at research firm Pharmarack, major firms including Cipla, Sun Pharma, Dr Reddy\u2019s Laboratories, Biocon, Natco, Zydus and Mankind Pharma are readying branded generics, with many more likely to follow. Prices are expected to fall sharply.<\/p>\n

Current monthly treatment costs are steep: Ozempic typically sells for 8,800 \u2013 11,000 rupees ($95-$119; \u00a371-\u00a389), while Wegovy can cost 10,000-16,000 rupees ($108-$173). Sapale expects generic competition to push that down to roughly 3,000-5,000 rupees ($36-54) per month.<\/p>\n

Lower prices could transform the market.<\/p>\n

India\u2019s anti-obesity drug sector \u2013 covering both injectables and oral medicines \u2013 has already grown rapidly, from roughly $16m in 2021 to close to $100m, according to Pharmarack. Demand accelerated after the launch of Rybelsus in 2022, the first oral version of semaglutide.<\/p>\n

The surge reflects a broader health shift.<\/p>\n

India already has more than 77 million people with type-2 diabetes and one of the world\u2019s largest populations of overweight adults. Urban lifestyles, carbohydrate-heavy diets and sedentary habits have helped drive both conditions.<\/p>\n

For doctors, cheaper GLP-1 drugs could soon add a powerful new tool to treat them.<\/p>\n

Weight-loss drugs are also moving beyond endocrinology clinics. Cardiologists use them to help patients shed weight before procedures such as angioplasty, orthopaedic surgeons to ease stress on joints before knee surgery, and chest physicians to treat conditions such as obstructive sleep apnoea.<\/p>\n

Muffazal Lakdawala, a Mumbai-based bariatric surgeon, says these drugs could dramatically expand treatment for India\u2019s large population of patients with diabetes and obesity.<\/p>\n

Until recently, he notes, access was limited: injectable GLP-1 drugs were expensive and difficult to obtain, while the oral drug Rybelsus was the only widely available option.<\/p>\n

\u201cIt is great that these will become cheaper so that more of the diabetic and obese Indian population can access them,\u201d he says.<\/p>\n

But he adds a warning: \u201cThe quality of the drugs being made here must be very tightly regulated.\u201d<\/p>\n

That caution reflects a broader reality about India\u2019s pharmaceutical industry \u2013 the global powerhouse behind low-cost generic medicines.<\/p>\n

The country is the world\u2019s largest supplier of generic medicines, producing roughly 60,000 brands across more than 60 therapeutic categories and accounting for around 20% of global generic supply.<\/p>\n

Its reputation as the \u201cpharmacy of the world\u201d rests largely on its ability to turn expensive medicines into affordable mass-market products.<\/p>\n

The most celebrated example came two decades ago, when Indian firms helped slash the price of HIV antiretroviral drugs, dramatically expanding treatment across Africa and the developing world.<\/p>\n

Today India supplies medicines to over 200 countries, meeting more than half of Africa\u2019s generic drug demand, about 40% of generics used in the US, and roughly a quarter of medicines in the UK.<\/p>\n

\u201cThe export potential of Indian generic weight-loss drugs is humongous,\u201d says Namit Joshi, chairman of Pharmaceuticals Export Promotion Council of India. \u201cThe US market alone could scale to $10bn within a few years as obesity rates drive demand.\u201d<\/p>\n

That would be a sizeable addition to India\u2019s pharmaceutical trade: the country\u2019s generic drug exports currently total $30.46bn, with the US already its largest market.<\/p>\n

Yet enthusiasm among doctors remains tempered by caution.<\/p>\n

GLP-1 drugs are powerful but not risk-free. Side-effects can include nausea, vomiting and digestive problems; rarer complications include gallstones or pancreatitis. Rapid weight loss without adequate protein intake or exercise can also lead to muscle loss.<\/p>\n

Doctors say many patients misunderstand the role of the drugs. Some expect dramatic weight loss within weeks, influenced by social-media hype and celebrity endorsements.<\/p>\n

Mumbai-based diabetologist Rahul Baxi says success depends not just on the drug but on \u201cright patient selection\u201d.<\/p>\n

Doctors look beyond Body Mass Index (BMI) \u2013 a basic measure of weight relative to height \u2013 to related conditions such as diabetes or high cholesterol. Lifestyle matters too: if a patient\u2019s diet remains unhealthy, the drug alone may not be enough.<\/p>\n

Patients often arrive seeking a quick fix. \u201cPeople come asking to lose 10kg in three months,\u201d Baxi says.<\/p>\n

Rapid weight loss can have downsides. Too fast, and patients may lose fat from the face, neck, arms and thighs, leaving them looking frail.<\/p>\n

\u201cGradual weight loss, slow dose escalation, and a focus on protein intake, exercise and strength training are key to healthier outcomes,\u201d says Baxi.<\/p>\n

Another challenge is that weight loss often reverses once the drugs stop. Appetite can rebound strongly as the body resists losing fat.<\/p>\n

\u201cIf you stop the drugs, the appetite comes back voraciously,\u201d Baxi says.<\/p>\n

There are also concerns about misuse as prices fall.<\/p>\n

Physicians report patients being prescribed high doses by gym trainers, beauty clinics or dieticians with no authority to do so. Online pharmacies sometimes dispense the drugs after cursory consultations. Beauticians already advertise rapid slimming \u201cpackages\u201d for weddings or social events.<\/p>\n

Such practices could spread as cheaper generics become more widely available.<\/p>\n

\u201cMore access to cheap drugs means a higher chance of abuse,\u201d says Bhaumik Kamdar, a Mumbai-based chest physician. \u201cAccess calls for more responsibility \u2013 and stricter regulation. I am cautiously optimistic about these drugs.\u201d<\/p>\n

That warning echoes Lakdawala\u2019s concerns about manufacturing standards.<\/p>\n

\u201cThese are very beneficial drugs,\u201d he says. \u201cWe don\u2019t want side effects arising from poor-quality medicines and giving the molecule itself a bad name.\u201d<\/p>\n

The government is also trying to temper the hype. In an advisory last week, India\u2019s drug regulator warned pharmaceutical companies against promoting prescription weight-loss medicines such as GLP-1 drugs directly to consumers.<\/p>\n

Advertising that promises dramatic results or downplays the need for diet and exercise could be deemed misleading, officials said, stressing that such medicines should only be used under medical supervision.<\/p>\n

For regulators and doctors alike, the coming months may therefore test whether India can balance affordability with oversight.<\/p>\n

Baxi says he asks patients to improve their lifestyle and diet before prescribing weight-loss drugs.<\/p>\n

Even then, they are first put on a higher-protein diet with a dietician\u2019s help, he says. Current evidence suggests the drugs may need to be taken over a long term. But many patients arrive asking for a \u201cquick fix after seeing Instagram reels\u201d, putting pressure on doctors.<\/p>\n

Yet, the rewards could be significant. A medicine that once cost tens of thousands of rupees a month could become accessible to millions \u2013 and perhaps eventually to patients far beyond India.<\/p>\n

\u201cI am actually writing on prescriptions to many patients: Come to me after 20 March when the prices come down,\u201d says Baxi.<\/p>\n

The post India\u2019s cheap weight-loss drugs could reshape global obesity fight<\/a> appeared first on KBC Digital<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

India could soon get a lot thinner \u2013 at least in theory. On Friday the patent on semaglutide \u2013 the molecule behind Danish drugmaker Novo Nordisk\u2019s blockbuster weight-loss drugs Wegovy and Ozempic \u2013 expires in the country. This will allow domestic pharmaceutical companies to release cheaper copies or generics, triggering a rush of competition that […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-134613","post","type-post","status-publish","format-standard","hentry","category-uncategorized","entry"],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/chezaspin.com\/blog\/wp-json\/wp\/v2\/posts\/134613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/chezaspin.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/chezaspin.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/chezaspin.com\/blog\/wp-json\/wp\/v2\/comments?post=134613"}],"version-history":[{"count":0,"href":"https:\/\/chezaspin.com\/blog\/wp-json\/wp\/v2\/posts\/134613\/revisions"}],"wp:attachment":[{"href":"https:\/\/chezaspin.com\/blog\/wp-json\/wp\/v2\/media?parent=134613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/chezaspin.com\/blog\/wp-json\/wp\/v2\/categories?post=134613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/chezaspin.com\/blog\/wp-json\/wp\/v2\/tags?post=134613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}